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Abstract
Background International research has focused on
screening and mass media campaigns to promote earlier
patient presentation and detect lung cancer earlier. This
trial tested the effect of a behavioural intervention in
people at increased risk of lung cancer on help-seeking
for respiratory symptoms.
Methods Parallel, individually randomised controlled
trial. Eligible participants were long-term smokers
with at least 20 pack-years, aged 55 and above. The
CHEST intervention entailed a consultation to discuss
and implement a self-help manual, followed by selfmonitoring reminders to encourage help-seeking for
respiratory symptoms. The control group received a brief
discussion about lung health. Both groups had baseline
spirometry. Telephone randomisation was conducted,
1:1, stratified Medical Research Council (MRC) dyspnoea
score and general practice. Participants could not be
blinded; data extraction and statistical analyses were
performed blinded to group assignment. The primary
outcome was respiratory consultation rates.
Results We randomised 551 participants (274
intervention, 277 control) from whom the primary
outcome was determined for 542 (269 intervention, 273
control). There was a 40% relative increase in respiratory
consultations in the intervention group: (adjusted rates
(95% CI) intervention 0.57 (0.47 to 0.70), control
0.41 (0.32 to 0.52), relative rate 1.40 (1.08 to 1.82);
p=0.0123). There were no significant differences in time
to first respiratory consultation, total consultation rates
or measures of psychological harm. The incremental costeffectiveness ratio was $A1289 per additional respiratory
consultation.
Conclusions A behavioural intervention can
significantly increase consulting for respiratory symptoms
in patients at increased risk of lung cancer. This
intervention could have an important role in primary care
as part of a broader approach to improve respiratory
health in patients at higher risk.
Trial registration number Australian New Zealand
Clinical Trial Registry (1261300039 3752). This was
registered pre-results.

Introduction

Lung cancer is the most common cancer worldwide and most common cause of cancer deaths.1
In Australia, there will be an estimated 12 741
new cases and 9198 deaths due to lung cancer in

Key messages
What is the key question?

►► Can a behavioural intervention, delivered in

primary care, to patients at increased risk of
lung cancer increase consulting for respiratory
symptoms as an approach to reducing time to
diagnose lung cancer?

What is the bottom line?

►► The CHEST intervention significantly increased

respiratory consultation rates in this population,
without causing psychological harm, but there
was no significant reduction in time to first
presentation.

Why read on?

►► This is the largest trial to date to test a tailored

behavioural approach to reduce diagnostic
delay for lung cancer. This targeted approach
could be an alternative to mass media symptom
awareness campaigns and support early
intervention to improve respiratory health in
long-term smokers in primary care.

2018.2 Although there have been recent improvements in outcomes for lung cancer, 5-year survival
in Australia is only 16%2 and less than 10% in the
UK.3 This is primarily because most patients are
diagnosed when curative surgical treatment is not
possible.3 4
There is growing evidence that time to diagnosis
in symptomatic patients is associated with clinical
outcomes for lung cancer.5 6Patient presentation
to healthcare and initial management in primary
care are key determinants of outcomes of patients
with cancer.7 The Model of Pathways to Treatment
describes symptom appraisal and help-seeking
intervals as key timepoints along the cancer diagnostic pathway which contribute to overall time to
diagnosis.8 9 Several studies have explored symptom
appraisal and help-seeking in people recently diagnosed with lung cancer, identifying factors contributing to later presentation to healthcare. These
include limited awareness of cancer symptoms, fear
of cancer,10 concerns about wasting their own and
general practitioners (GPs)’ time,11 stoicism12 13 and
stigma around smoking.14 15 Current smokers are
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Methods

As we have published the trial protocol,26 we report the methods
here in brief.

Trial design

Individually randomised controlled trial conducted in 11 general
practices in Perth, Western Australia, and 6 in Melbourne,
Victoria, Australia.

Participants

Eligible participants were long-term smokers with at least 20
pack-years, aged 55 and above, including ex-smokers if their
cessation date was less than 15 years ago. Participants were able
to read and write English and give informed consent. Exclusion criteria included severe psychiatric or cognitive disorder or
previous diagnosis of lung cancer.
Patients who potentially met eligibility criteria were identified
from the general practice electronic medical record using the
Emery JD, et al. Thorax 2019;74:362–370. doi:10.1136/thoraxjnl-2018-212506

Canning data extraction software (www.canningtool.com.au).
They were invited to participate in the study by letter from their
general practice. Invitations included a patient information sheet
and expression of interest form, which included four screening
questions to assess smoking pack-years. Non-responders were
followed up after 2 weeks with a reminder postcard. Eligible
patients returning an expression of interest form were followed
up by telephone to make a trial appointment at their general
practice. Randomisation was performed after completion of
baseline data and written informed consent had been obtained.

Intervention

A trained researcher performed spirometry and then guided the
participant through a self-help manual, entitled Chest Symptoms
that Call for Action.27 The key objectives of the manual were
to: increase the salience and personal relevance of symptoms,
improve knowledge of symptoms by introducing chest disease
prototypes, reinforce the benefits of early intervention in lung
cancer and other chest disease, and sanction early consultation.
‘If-then’ action plans were developed with the participant, linked
to symptom checklists, and ‘If-then’ coping plans discussed to
tackle barriers to consultation. A range of monthly prompts to
monitor current symptoms were tailored to individual preferences, including SMS and email reminders, postcards, phone
calls and fridge magnets.

Control

A trained researcher performed spirometry and then had a brief
general discussion about lung health. This was designed as an
attention control and to increase overall engagement in the trial
for control participants. Participants then received usual care at
their general practice.
In both trial groups, the results of the spirometry were sent to
the participant’s GP for follow-up according to usual practice.

Outcomes and measures

The primary outcome of this trial was consultation rates
for respiratory symptoms. Data on consultations in the year
before the trial and for 12 months after the consultation were
collected through audit of GP records. This was a phase II trial
of a complex intervention28; our outcomes were designed to test
whether the intervention has the potential to facilitate the early
detection of lung cancer by evaluating its effect across a range of
intermediate endpoints.

Additional measures included

1. Demographics and clinical variables: age, gender, marital status, postcode, highest education level, occupation, Medical
Research Council (MRC) Dyspnoea Scale29 and lung function at baseline only.
2. Self-efficacy for consulting without delay: a 10-item self-completed scale summed to score 10–100.25
3. Knowledge of symptoms of lung disease: a 21-item self-completed checklist of possible symptoms expressed as a percentage correctly selected as associated with chest disease.25
4. Symptom appraisal and help-seeking intervals measured
using the SYMPTOM instrument (lung cancer version), a
self-completed questionnaire that obtains data on presenting
symptoms and their duration prior to consultation.30 Monthly electronic searches of the GP medical records identified
recent respiratory consultations. Participants were sent a
SYMPTOM questionnaire to complete about symptoms relating to that consultation.
363
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more likely to experience respiratory symptoms but less likely
to consult about them.16 Studies in rural Western Australia have
found that normalisation of respiratory symptoms is common,
especially in those with respiratory comorbidities, with median
patient delays to seek help of 50–80 days.17 18 These times should
be compared with lung cancer median volume doubling times of
98 days suggesting such delays could be clinically significant.19
The US National Lung Cancer Screening Trial found a 20%
relative reduction in lung cancer mortality from annual low-dose
CT,20 but the limited cost-effectiveness21 and feasibility of implementing national lung cancer screening programmes22 means that
other approaches to timely diagnosis of lung cancer are needed.
The search for useful biomarkers of lung cancer shows promise,
but is still at the validation stage.23 An alternative strategy is to
attempt to diagnose lung cancer earlier through prompt recognition and investigation of symptoms suggestive of the disease,
particularly in those at higher risk of lung cancer.
Mass media campaigns to raise symptom awareness have
shown variable evidence of effect. Data from the ‘Be Clear on
Cancer’ campaigns in England, have suggested potentially useful
short-term effects including increased presentations to general
practice and detection of earlier stage lung cancer, but these
are based on comparisons with historical control data.24 A trial
in rural Western Australia of a mass media campaign, which
included lung cancer symptom awareness, failed to demonstrate an effect on time of presentation to healthcare or time to
diagnosis.17
Instead of mass media approaches, more targeted interventions
could promote earlier presentation to healthcare in individuals at
increased risk of lung cancer. The CHEST Trial in Scotland was
the first to show preliminary evidence that this approach could
alter overall consulting patterns in this population.25 In that trial,
a theoretically based intervention delivered in primary care to
patients at increased risk of lung cancer significantly increased
the overall consultation rate by 15%; it was not powered to
detect differences in respiratory consultations.
We have adapted the Scottish CHEST intervention for an
Australian population. While maintaining its core theoretical
elements, we modified the language and format of the self-help
manual and expanded approaches to prompt symptom monitoring. We report the results of the CHEST Australia Trial which
aimed to test the modified CHEST Intervention in an Australian
primary care population and measure its effect on consultation
rates for respiratory symptoms.

Lung cancer

5. Hospital Anxiety and Depression Scale (HADS).31
6. Cancer-worry scale: a 6-item self-completed scale, adapted
from the breast cancer worry scale and validated in the Scottish CHEST Trial.25 32
7. Quality of life using the Assessment of Quality of Life
(AQoL-8D).33
8. Heath service utilisation: in addition to the primary measure
of consultation rates for respiratory symptoms, total general
practice consultation rates, chest X-ray requests and referrals to respiratory physicians were captured through audit of
364

general practice medical records. Participants consented to
access to their Medicare claims data (Pharmaceutical Benefits
Scheme (PBS) and Medicare Benefits Schedule (MBS)) obtained from the Department of Human Services. Medicare is
the publicly funded universal healthcare system in Australia.
Claims data provided more complete information about visits to other general practices, including prescribing, investigations and referrals arising from these.
Participant-completed measures were collected at baseline, 1 and 12 months, with the exception of the SYMPTOM
Emery JD, et al. Thorax 2019;74:362–370. doi:10.1136/thoraxjnl-2018-212506
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Figure 1 Trial flow chart. GP, general practitioner.

Lung cancer

Characteristic

Intervention (N=274)

Female

117 (42.7%)

114 (41.2%)

Male

157 (57.3%)

163 (58.8%)

Age: mean (SD) (n)
Sex

Control
(N=277)

Level

64.38 (9.8) (274)

64.07 (10.64) (277)

FEV1: mean (SD) (n)

80.90 (21.65) (273)

81.63 (20.51) (276)

Smoking pack-years: mean (SD) (n)

45.18 (23.84) (274)

45.99 (24.4) (277)

Smoking status
Comorbidities

Ex-smoker

168 (61.3%)

148 (53.4%)

Current

106 (38.7%)

129 (46.6%)

Cardiovascular

100 (36.5%)

115 (41.5%)

Respiratory

90 (32.8%)

89 (32.1%)

Psychiatric

44 (16.1%)

41 (14.8%)

Diabetes

28 (10.2%)

35 (12.6%)

Other

92 (33.6%)

92 (33.2%)

Respiratory consultations from 12 months to baseline: mean (SD) (n)

0.86 (1.62) (269)

All consultations from 12 months to baseline: mean (SD) (n)

9.06 (7.49) (270)

Accommodation

204 (74.5%)

212 (76.5%)

Rent your home

50 (18.2%)

33 (11.9%)

Other (please specify below)

20 (7.3%)

22 (7.9%)

0
86 (31.4%)

89 (32.1%)

Year 12 or equivalent

40 (14.6%)

38 (13.7%)

Trade/apprenticeship

29 (10.6%)

39 (14.1%)

Tertiary certificate/diploma

49 (17.9%)

57 (20.6%)

Undergraduate university degree

24 (8.8%)

17 (6.1%)

Postgraduate university degree

17 (6.2%)

12 (4.3%)

Other (please specify)

26 (9.5%)

17 (6.1%)

3 (1.1%)

8 (2.9%)

70 (25.5%)

70 (25.3%)

166 (60.6%)

166 (59.9%)

32 (11.7%)

28 (10.1%)

Other (please specify below)

6 (2.2%)

5 (1.8%)

Missing

0

On your own
With a partner/spouse
With other family

Occupation (more than one can apply)

10 (3.6%)

Year 11 or below

Missing
Living arrangements

9.11 (7.70) (273)

Own your home

Missing
Education

0.76 (1.25) (273)

8 (2.9%)

Retired

85 (31.0%)

98 (35.4%)

Caring for dependent relative

14 (5.1%)

16 (5.8%)

Voluntary worker

20 (7.3%)

14 (5.1%)

Unemployed

52 (19.0%)

63 (22.7%)

Student

8 (2.9%)

3 (1.1%)

Looking after home/family

43 (15.7%)

48 (17.3%)

Disabled/unable to work

21 (7.7%)

22 (7.9%)

instrument as already described. Health service utilisation data
were collected at 12 months from an audit of general practice
medical records and obtaining Medicare claims data.

Sample size

Data from the Scottish trial was used to inform power calculations.25 Assuming that the primary endpoint of consultations for
respiratory symptoms follows a Poisson distribution, and that the
expected average rate over 12 months in the study population
would be 1.06 for control patients and 25% higher for intervention patients, a sample of 534 would provide at least 80%
Emery JD, et al. Thorax 2019;74:362–370. doi:10.1136/thoraxjnl-2018-212506

power to reject the null hypothesis of no difference between the
groups at the two-sided 5% level of significance. Accounting for
the same attrition rate observed in the Scottish CHEST trial, we
required a total sample of 550 participants.

Randomisation

Those who met the eligibility criteria and who consented to
participate were randomised 1:1 to either the control or intervention. Randomisation was performed using a centralised independent telerandomisation system managed by the National
Health and Medical Research Council (NHMRC) Clinical Trials
365
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Table 1 Baseline characteristics

Lung cancer
Respiratory and total consultations at 12 months

Characteristic

Level

Mean respiratory
consultations during
12-month follow-up
(SD) (n)
Number of respiratory
consultations during
12-month follow-up

0.67 (1.01) (269)

Control
(N=277)
0.47 (0.78) (273)

Covariates in negative
binomial model

Relative rate adjusted for
covariate (95% CI)

Treatment group only

1.42 (1.08 to 1.87), p=0.0118

1.35 (1.04 to 1.74), p=0.0227

<0.0001

58 (20.9%)

  Pack-years

1.40 (1.07 to 1.82), p=0.0125

0.2513

22 (7.9%)

  Age

1.40 (1.07 to 1.81), p=0.0128

0.0122

9 (3.2%)

  FEV1

1.37 (1.06 to 1.77), p=0.0159

<0.0001

0

  Gender

1.40 (1.08 to 1.83), p=0.0115

0.3145

1 (0.4%)

0

  Smoker

1.39 (1.07 to 1.82), p=0.0142

0.7077

5 (1.8%)

4 (1.4%)

 MRC dyspnoea (1–2 vs 3–4) 1.41 (1.08 to 1.83), p=0.0110

0.0728

9.05 (7.53) (268)

8.98 (8.14) (273)

 Cardiovascular comorbidity

1.37 (1.05 to 1.78), p=0.0188

0.0756

 Respiratory comorbidity

1.38 (1.08 to 1.78), p=0.0112

<0.0001

 Psychiatric comorbidity

1.40 (1.08 to 1.81), p=0.0100

0.9965

  Diabetes

1.40 (1.08 to 1.83), p=0.0116

0.4836

1.41 (1.08 to 1.84), p=0.0103

0.2033

162 (59.1%)

184 (66.4%)

1

59 (21.5%)

2

27 (9.9%)

3

17 (6.2%)

4

3 (1.1%)

5
Missing

No

21 (7.7%)

25 (9.0%)

 Other comorbidity

Yes

247 (90.1%)

248 (89.5%)

GP, general practitioner.

6 (2.2%)

4 (1.4%)

Centre, based at the University of Sydney. Stratifying variables
for randomisation were MRC dyspnoea score (scores 1–3 and
4–5) and general practice recruitment site.

Blinding

Outcomes assessed by self-report obviated the need for researcher
blinding. For the extraction and analysis of health service utilisation data, research staff were blinded to group assignment. All
statistical analyses were performed blinded to group assignment.

Statistical methods

P-value for
covariate listed

 Respiratory consultations
from 12 months to baseline

0

Missing

All randomised patients were considered eligible for inclusion
in the analysis in accordance with the intention-to-treat analysis principle. In accordance with the provision specified in the
statistical analysis plan, a negative binomial model was used for
the analysis of data on consultation rates because of overdispersion that rendered the Poisson model inappropriate. The
model included general practice as a fixed effect and accounted
for additional variation due to repeat consultations by the same
participant. The effect of clustering arising from couples being
randomised together was explored by fitting the model using
the method of generalised estimating equations. Comparisons between groups on continuous secondary endpoints were
performed using a linear model that included general practice
as a factor and the baseline value as a covariate (where applicable). Comparisons between groups on categorical secondary
endpoints were performed using logistic regression with general
practice fitted as a factor. The analyses performed on the primary
and secondary endpoints were repeated adjusting for additional
baseline covariates (eg, number of consultations in 12 months
prior to randomisation, gender, comorbidities, smoking status,
MRC dyspnoea score) as part of a sensitivity analysis. A mixed
model for repeated measures was applied to the scale scores
from patient-reported outcomes and included covariates for
general practice, treatment allocation, timepoint, baseline and a
timepoint-by-treatment allocation interaction. Survival analysis
methods (including the log-rank test and proportional hazards
366

Table 3 Secondary analysis of respiratory consultations adjusting for
other baseline covariates

GP site plus the following
covariate:

Mean total
consultations during
12-month follow-up
(SD) (n)
At least one
consultation during
12-month follow-up

Intervention
(N=274)

regression) were used to compare randomised groups on time to
first consultation for a respiratory symptom from baseline.
Costs of delivering the CHEST intervention were calculated to include: identification of the at-risk population, invitation processes, training to deliver the CHEST intervention,
consultation time (assuming delivered by a practice nurse),
spirometry equipment including laptop computer, and patient
reminders. Total health service costs were derived by multiplying the resource used by the relevant MBS and PBS fee;
these data included patient copayment contribution. Costs are
reported as undiscounted cost for 2016. We calculated an incremental cost-effectiveness ratio (ICER) per additional respiratory
consultation. We performed sensitivity analyses including the
costs of spirometry equipment as this was not a core part of the
intervention.

Results

Between 29 May 2013 and 19 November 2015, we approached
2501 current and 2666 ex-smokers, and 112 with unclear quit
status; 940 of these (17.8%) responded. Of these, 623 (66%)
met our eligibility criteria and 551 (88%) consented to be
randomised (see figure 1).
Table 1 presents baseline data on the trial cohort. Patients
who did not respond to the initial trial invitation were similar in
terms of age (mean 65.7 years) and sex (56.0% male) but were
more likely to be current smokers (48.0% vs 42.6%). There was
a higher proportion of current smokers in the control than intervention group (46.6% vs 38.7%) but no other between-group
imbalances. Three patients were diagnosed with lung cancer
during the 12-month follow-up, two in the intervention group
and one in the control group.
The primary outcome was determined for 542 participants
(98.3%); 12-month questionnaire data were available on 416
participants (intervention 212 (77%); control 204 (74%)).
SYMPTOM questionnaires were completed for 88% of intervention and 66% of control consultations.
Table 2 presents data on total GP consultations and those for
respiratory symptoms. On average, the overall cohort consulted
their GP approximately nine times over the 12-month follow-up
Emery JD, et al. Thorax 2019;74:362–370. doi:10.1136/thoraxjnl-2018-212506
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Table 2

Lung cancer

Month

Randomised group N

Mean

SD

Min

Max

LS mean

LS Mean
difference

Lower
95% CL

Upper
95% CL

P-value for
difference

P-value for
difference rank
analysis

−0.2

−0.7

0.3

0.3954

0.6054

−0.1

−0.6

0.4

0.6083

0.5179

−0.3

−0.7

0.1

0.1557

0.1218

−0.2

−0.7

0.2

0.3672

0.3344

−0.2

−0.7

0.2

0.3381

0.4166

−0.3

−0.7

0.2

0.2436

0.1576

1.2

−0.9

3.2

0.2562

0.1915

0.7

−1.4

2.8

0.5111

0.5923

Anxiety
 0

Control

268

5.6

4.1

0.0

21.0

 0

Intervention

269

5.7

3.9

0.0

21.0

 1

Control

223

5.3

4.2

0.0

18.0

5.5

 1

Intervention

234

5.3

4.0

0.0

20.0

5.3

 12

Control

204

5.2

4.2

0.0

18.0

5.6

 12

Intervention

212

5.3

4.1

0.0

19.0

5.4

 0

Control

268

4.4

3.8

0.0

20.0

 0

Intervention

269

4.1

3.4

0.0

19.0

 1

Control

223

4.3

4.1

0.0

21.0

4.2

 1

Intervention

234

3.9

3.5

0.0

16.0

3.9

 12

Control

204

4.4

4.1

0.0

21.0

4.2

 12

Intervention

212

3.9

3.5

0.0

19.0

4.0

 0

Control

268

3.4

3.2

0.0

17.0

 0

Intervention

269

3.4

3.2

0.0

17.0

 1

Control

223

3.3

3.3

0.0

16.0

3.7

 1

Intervention

234

3.2

3.1

0.0

18.0

3.5

 12

Control

204

2.9

3.0

0.0

16.0

3.5

 12

Intervention

212

2.8

3.2

0.0

18.0

3.2

 0

Control

268

76.5

13.6

23.4

124.8

 0

Intervention

268

77.1

12.2

27.7

115.6

 1

Control

221

77.5

15.9

11.4

124.8

78.1

 1

Intervention

234

79.6

14.2

31.2

124.8

79.3

 12

Control

203

77.2

14.5

20.6

124.8

78.1

 12

Intervention

213

79.1

15.1

27.0

124.8

78.8

Depression

Cancer worry

Quality of life

AQoL, Assessment of Quality of Life; CL, confidence limit; HADS, Hospital Anxiety and Depression Scale; LS, least square; Max, maximum; Min, minimum.

period, but the majority did not consult at all about respiratory
symptoms (intervention 59.5% vs control 66.4%). In the negative
binomial model, with trial group and practice site as covariates,
there was a 40% relative increase in respiratory consultations
in the intervention group: (adjusted rates (95% CI) intervention 0.57 (0.47 to 0.70), control 0.41 (0.32 to 0.52), relative
rate 1.40 (1.08 to 1.82); p=0.0123). This effect remained
after adjusting for additional baseline covariates (table 3). In
the negative binomial model, with trial group and practice site
as covariates, there was no difference between groups on total
consultation rates: (adjusted rates (95% CI), intervention 8.52
(7.63 to 9.52), control 8.45 (7.51 to 9.50), relative rate 1.01
(0.88 to 1.16); p=0.8998).
Table 4 presents the results of mixed model repeated measures
analyses of HADS, cancer worry and AQoL-8D data. There were
no statistically significant differences between trial groups in
depression, general or cancer-specific anxiety, or quality of life.
Table 5 shows that there were no significant differences between
trial groups over time in perceived risk, self-efficacy to consult
or knowledge of symptoms lung disease.
Table 6 presents the results on time from onset of respiratory
symptom to GP consultation, for all consultations combined
and for each serial consultation. Figure 2 presents the survival
analysis curves for time to first respiratory consultation. In the
Emery JD, et al. Thorax 2019;74:362–370. doi:10.1136/thoraxjnl-2018-212506

survival analyses, there was no significant difference in time to
first respiratory consultation (log-rank test : χ2 1.5923 (degrees
of freedom (df) 1), p>χ2 0.207) or time to present for all consultations (HR 0.827; 95% CI 0.64 to 1.07; p=0.147).
There were 46 chest X-rays ordered in the intervention group
(mean 0.24 per person) and 50 in the control group (mean 0.25
per person). We were unable to identify accurately all referrals
to respiratory specialists. The cost of the CHEST intervention
(base case) was $A207.77 (SD $A99.22) per participant in the
intervention group. Based on the adjusted respiratory consultation rate at 12 months, this equates to an ICER per additional
respiratory consultation of $A1289. In the sensitivity analysis,
including the costs of spirometry equipment, the CHEST intervention cost $A816.91 (SD $A606.75) per participant in the
intervention group, with an ICER of $A5105 per additional
respiratory consultation.

Discussion
Summary
This is the largest trial yet to test the effect of a behavioural intervention to promote help-seeking in patients at increased risk of
lung cancer. We demonstrated a statistically significant 40%
relative increase in consultations about respiratory symptoms
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Table 4 HADS, cancer worry and AQoL-8D over time and between groups

Lung cancer

Month

Perceived risk, self-efficacy and knowledge scores over time and between group
Randomised
group

N

Mean

SD

Min

Max

LS mean

LS mean
difference

Lower
95% CL

Upper
95% CL

P-value for
difference

P-value for
difference rank
analysis

0.2

−0.0

0.5

0.0728

0.0836

0.1

−0.2

0.3

0.6452

0.4904

2.4

−0.9

5.7

0.1583

0.1207

2.4

−1.0

5.9

0.1695

0.1683

0.1

−0.8

1.1

0.7769

0.4583

1.0

−0.0

2.0

0.0509

0.0271

Perceived risk
 0

Control

268

6.9

1.9

0.0

10.0

 0

Intervention

269

6.9

1.7

0.0

10.0

 1

Control

223

6.7

2.0

0.0

10.0

6.8

 1

Intervention

234

7.0

1.7

2.0

10.0

7.1

 12

Control

204

6.7

1.9

0.0

10.0

6.8

 12

Intervention

212

6.7

1.9

0.0

10.0

6.8

 0

Control

268

85.0

24.2

0.0

110.0

 0

Intervention

269

87.3

24.6

0.0

110.0

 1

Control

222

89.1

21.7

0.0

110.0

89.8

 1

Intervention

234

92.4

19.6

7.0

110.0

92.2

 12

Control

204

90.7

20.0

0.0

110.0

91.7

 12

Intervention

212

94.5

17.5

0.0

110.0

94.1

Self-efficacy

Knowledge
 0

Control

268

9.0

5.4

−8.0

19.0

 0

Intervention

269

8.7

5.9

−10.0

19.0

 1

Control

223

9.4

5.4

−9.0

19.0

9.5

 1

Intervention

234

9.4

6.2

−13.0

21.0

9.6

 12

Control

204

8.8

5.9

−11.0

19.0

8.9

 12

Intervention

212

9.7

6.1

−8.0

19.0

9.9

CL, confidence limit; LS, least square; Max, maximum; Min, minimum.

in those receiving the intervention but no overall increase in
consultation rates. There was a non-significant mean reduction
of 14 days in time to first presentation with respiratory symptoms. There was no evidence of psychological harm from the
intervention.

Limitations

This was designed as a phase II efficacy trial of a complex intervention.28 The primary outcome of respiratory consultation rates is
based on the intervention logic model: by encouraging patients at
increased risk of lung cancer to consult their GP when they develop
respiratory symptoms, this would reduce the diagnostic delay of lung
cancer and potentially result in the detection of earlier stage disease.
Our primary outcome is, therefore, a suitable intermediate measure
along this causal pathway. However, even in this population at

Table 6

Time from symptom onset to consultation

Characteristic

Intervention
(N=274)

Control
(N=277)

All consultations: mean days
(SD) (n)

66.99 (109.18) (107)

76.32 (102.31) (94)

Median days (min–max)

21 (1–365)

30 (2–365)

Appointment 1: mean (SD) (n)

62.5 (102.26) (76)

76.29 (102.52) (70)

Median days (min–max)

21 (2–365)

30 (2–365)

Appointment 2: mean (SD) (n)

71.22 (119.75) (23)

83.85 (111.74) (20)

14 (3–365)

30 (2–365)

Median days (min–max)
Appointment 3: Mean (SD) (n)
Median days (min–max)

  68 (132.63) (7)
7 (1–365)

39.25 (37.85) (4)
30 (7–90)

Appointment 4: mean (SD) (n)

304 (-) (1)

-

Median days (min–max)

304 (304–304)

-
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increased risk of lung cancer, during a 12-month follow-up period,
only three participants (0.54%) were diagnosed with lung cancer.
It would require a substantially larger trial to be powered even to
detect differences in time to diagnosis of lung cancer, let alone in
clinical outcomes such as lung cancer stage or mortality. The control
group received spirometry and a brief discussion about lung health.
This was intended as an attention control but could potentially have
also increased consultation rates for respiratory symptoms. There
was also a chance imbalance between groups, with a higher proportion of current smokers in the control group. Both of these limitations could have reduced the estimated effect size of the CHEST
intervention. We achieved a very low attrition rate for the primary
outcome (98.3%), but we had greater loss-to-follow-up for the

Figure 2 Survival curve for time from symptom onset to first
consultation.
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Table 5

Lung cancer

Generalisability

We recruited patients from general practices in two large Australian cities and from suburbs with a range of socioeconomic deprivation. Patients at increased risk of lung cancer are a ‘hard-to-reach’
group due to smoking stigma and socioeconomic deprivation. The
response rate to the mailed invitation into the trial was 18% of
whom only 66% were eligible. Our final accrual rate was 10.6%;
while participants had a similar age and sex distribution to non-responders, there was a higher proportion of ex-smokers in the trial
(60% vs 51% in the invited population). It is possible that there was
a selection bias towards those with less severe respiratory disease
given the low rate of baseline respiratory consultations and lung
function results. It is difficult to know in which direction this bias
might affect our estimate of the effect size of the CHEST intervention. Current smokers may have greater barriers to consulting and
therefore we might have seen a larger effect size in a less biased
sample. Alternatively, those with more severe respiratory disease
may be more frequent consulters at baseline, thereby reducing any
potential effect on consultation rates.

Interpretation

Previous research in England found that patients at increased risk
of lung cancer commonly have symptoms associated with lung
cancer but many do not seek help about these symptoms.11 34
Smokers in particular are less likely than non-smokers to consult
their GP when they develop respiratory symptoms.16 Non-consulters have higher tolerance for their symptoms, are more likely
to self-manage and have greater concern about wasting their GP’s
time.11 Qualitative research with GPs has questioned the value
of mass media symptom awareness campaigns due to concerns
about overwhelming the health system.35 Together, these findings have led to calls for targeted interventions in primary care
to improve symptom recognition and empower help-seeking in
patients at increased risk of lung cancer.16 35
Our parallel qualitative evaluation of the CHEST trial
confirmed the theoretical underpinning of the intervention:
we found evidence of reduction in stigma and guilt, increase in
salience and personal relevance of symptoms and sanctioning
of help-seeking,15 which translated into increased respiratory
consultations. Of interest, in the trial we found no difference in
our quantitative measures of knowledge, self-efficacy to consult,
risk perception or measures of general and cancer-specific
anxiety. We measured anxiety as a potential harm of the intervention. The theoretical models underpinning the CHEST intervention did not suggest we needed to create anxiety to have an
effect; indeed, fear of cancer can be a barrier to help-seeking.10
The CHEST intervention did not alter overall consultation rates
but had a specific effect on help-seeking for respiratory symptoms. Although it prompted more respiratory consultations,
there was only a small reduction in the duration of symptoms
before seeking help; an average of 14 days earlier for the first
consultation and 9 days for all respiratory consultations. Participants in the intervention group took an average of 2 months from
symptom onset to consult about a new respiratory symptom.
This size of effect is unlikely to be of clinical significance. The
intervention made it more likely that someone would present
with respiratory symptoms, but further consideration is required
Emery JD, et al. Thorax 2019;74:362–370. doi:10.1136/thoraxjnl-2018-212506

on how to prompt even earlier presentation with these symptoms. It may be that additional interventions aimed at the GP
are required. Patients with lung cancer often have multiple GP
visits about respiratory symptoms before referral to a specialist
for definitive diagnosis.36 By highlighting that these patients are
at increased risk of lung cancer, they could potentially be investigated sooner by their GP and reduce the overall diagnostic
interval.37
The CHEST intervention cost $A1289 per additional respiratory consultation. In the absence of trial data with sufficient
numbers of lung cancer cases, it is difficult to estimate the cost
per lung case detected. If we assume that 3% of these consultations led to a diagnosis of lung cancer,38 this would equate to
approximately $A42 500 per case detected.
Significant uncertainty therefore remains about the best
strategies to promote earlier detection of lung cancer. The US
Preventive Services Taskforce has recommended low-dose CT
screening for adults aged 55 to 80 years with at least a 30 packyear smoking history.39 Other countries are still considering the
evidence to inform national policy. In Australia, the cost-effectiveness of lung cancer CT screening is estimated at $A2 33 000
per quality-adjusted life-year gained, making it less likely to be
implemented in the near future.21 There are other limitations
of focusing on low-dose CT screening as the main strategy for
early detection of lung cancer. Low-dose CT is more effective at
detecting parenchymal lung tumours and can miss small endobronchial cancers40 which are common among smokers and can
potentially produce early symptoms. Interval lung cancers occur
even with annual CT screening and will present symptomatically
at a more advanced stage.41 Even within the context of national
cancer screening programmes for breast and bowel cancer, the
majority of these cancers are not detected via screening, due to
low participation rates and interval cancers.42
A key implementation challenge for CT screening is the
identification of the screening population.22 The findings of
the CHEST Australia trial should perhaps be considered in the
broader context of respiratory disease management in primary
care including lung cancer and COPD. International guidelines
currently do not recommend screening for COPD, but instead
suggest a case-finding approach in patients at risk of the condition who have respiratory symptoms.43 44 The CHEST intervention could therefore be a way to identify patients at increased risk
of either lung cancer or COPD and include spirometry as part
of a respiratory health consultation. In those at very high risk
of lung cancer (eg, more than 30 pack-years smoking history),
low-dose CT screening would be recommended in some countries. For those at moderate risk of lung cancer, the behavioural
CHEST intervention could raise patient awareness of respiratory
symptoms, reduce stigma and promote help-seeking. This could
potentially improve the management of COPD and prompt
earlier assessment by their GP for lung cancer. The CHEST
intervention is a relatively low-cost option which might have
broader implications for improving the management of respiratory symptoms, and serious lung disease, in primary care.
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patient-reported outcomes. In particular, there was greater attrition
for responses to the SYMPTOM questionnaire in the control group.
This might have biased our estimates of the effect of the intervention on time to GP consultation but it is difficult to know in which
direction.
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